



1/21




FIG. 1B




FIG. 1A




FIG.2A-1




FIG.2A-2




FIG.2A-3



3/21




FIG.2A-4




FIG.2A-5




FIG.2A-6



4/21




FIG.2B-1




FIG.2B-2




FIG.2B-3




FIG.2B-4




FIG.2B-5




FIG.2B-6




FIG.2B-7




FIG.2B-8




FIG.2B-9




FIG.2B-10




FIG.2B-11




FIG.2B-12



8/21




FIG.3A-2




FIG.3A-1

	Pi	0.1% LPS	40% TFE
CAP18	8.1	39.2	84.6
CAP18-21a	7.7	19.2	97.0
CAP18-18	3.8	13.4	64.8
CAP18-17	3.1	14.6	68.8
CAP18-15a	2.7	11.5	44.7

FIG.3A-3



9/21




FIG.3B-2




FIG.3B-1



10/21




FIG. 3B-4




FIG. 3B-3

	Pi	0.1% LPS	40% TFE
SMAP29	12.6	30.1	80.9
SMAP29-18	2.0	16.4	45.4
SMAP29X-18A	45.6	-	88.8
SMAP29X-14A	13.9	-	77.4

FIG. 3B-5



11/21




FIG.4A-1




FIG.4A-2



12/21




FIG.4A-3




FIG.4A-4




FIG.4A-5




FIG.4B



14/21




FIG.5A-1




FIG.5A-2



15/21




FIG.5B-1




FIG.5B-2



16/21




FIG.5B-3



17/21

SMAP29 is Efficacious in an *In Vivo* Ovine Model of Acute Pneumonia




FIG.6



18/21





FIG. 7



19/21




FIG. 8



20/21




FIG.9B




FIG.9A



21/21




FIG.10B




FIG.10A